🇺🇸 FDA
Pipeline program

PEMBROLIZUMAB , Matching placebo, EIK1001 solution for injection 1.0 mg/mL free base equivalent

EIK1001-006

Phase 3 small_molecule active

Quick answer

PEMBROLIZUMAB , Matching placebo, EIK1001 solution for injection 1.0 mg/mL free base equivalent for Advanced Melanoma is a Phase 3 program (small_molecule) at Eikon Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Eikon Therapeutics
Indication
Advanced Melanoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials